Significance of serum tumor necrosis factor-alpha and its combination with HER-2 codon 655 polymorphism in the diagnosis and prognosis of breast cancer

International Journal of Biological Markers

Volumn 25, Issue 3, 2010, Pages 126-135

  Papadopoulou, Evropi ^a   Tripsianis, Gregory ^a   Anagnostopoulos, Konstantinos ^a   Tentes, Ioannis ^a   Kakolyris, Stylianos ^a   Galazios, Georgios ^a   Sivridis, Efthimios ^a   Simopoulos, Konstantinos ^a   Kortsaris, Alexandros ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Breast cancer; HER 2; Polymorphism; Serum TNF alpha; Survival

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER INVASION; CANCER PATIENT; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CASE CONTROL STUDY; CLINICAL EVALUATION; CODON; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENOTYPE; HUMAN; HUMAN TISSUE; LYMPH NODE; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIMARY TUMOR; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 78650820824     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.1177/172460081002500302     Document Type: Article

References (54)

1. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001; 104: 487-501.
2. MacEwan DJ. TNF receptor subtype signalling: differences and cellular consequences. Cell Signal 2002; 14: 477-92.
3. Anderson GM, Nakada MT, DeWitte M. Tumor necrosis factor-alpha in the pathogenesis and treatment of cancer. Curr Opin Pharmacol 2004; 4: 314-20.
4. Thomsen LL, Lawton FG, Knowles RG, et al. Nitric oxide synthase activity in human gynecological cancer. Cancer Res 1994; 54: 1352-4.
5. Jaiswal M, LaRusso NF, Burgart LJ, Gores GJ. Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res 2000; 60: 184-90.
6. Cui LF, Guo XJ, Wei J, et al. Overexpression of TNF-α and TNFRII in invasive micropapillary carcinoma of the breast: clinicopathological correlations. Histopathology 2008; 53: 381-8.
7. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
8. Szlosarek P, Charles KA, Balkwill FR. Tumour necrosis factor-alpha as a tumour promoter. Eur J Cancer 2006; 42: 745-50.
9. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-12.
10. Revillion F, Bonneterre J, Peyrat JP. ERB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer 1998; 34: 791-808.
11. Menard S, Pupa SM, Campiglio M, Tagliabue E. Biologic and therapeutic role of HER2 in cancer. Oncogene 2003; 22: 6570-8. (Pubitemid 37372337)
12. Ross JS, Fletcher JA, Linette GP, et al. The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 2003; 8: 307-25.
13. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 1998; 58: 2825-31. (Pubitemid 28311914)
14. Zhou BP, Hu MC, Miller SA, et al. HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NFkB pathway. J Biol Chem 2000; 275: 8027-31.
15. Papewalis J, Nikitin A, Rajewky MF. G to A polymorphism at amino acid codon 655 of the human erbB-2/HER-2 gene. Nucleic Acids Res 1991; 19: 5452.
16. Takano K, Ogasahara K, Kaneda H, et al. Contribution of hydrophobic residues to the stability of human lysozyme: calorimetric studies and X-ray structural analysis of the five isoleucine to valine mutants. J Mol Biol 1995; 254: 62-76.
17. Xie D, Shu X, Deng Z, et al. Population-based, case-control study of HER-2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 2000; 92: 412-7. (Pubitemid 30154823)
18. Kalemi T, Lambropoulos A, Gueorguiev M, et al. The association of p53 mutations and p53 codon 72, Her2 codon 655 and MTHFR C677T polymorphisms with breast cancer in Northern Greece. Cancer Lett 2005; 222: 57-65.
19. Keshava C, McCanlies EC, Keshava N, Wolff MS, Weston A. Distribution of HER2V655 genotypes in breast cancer cases and controls in the United States. Cancer Lett 2001; 173: 37-41.
20. Rutter JL, Chatterjee N, Wacholder S, Struewing J. The HER2 I655V polymorphism and breast cancer risk in Ashkenazim. Epidemiology 2003; 14: 694-700.
21. Zubor P, Vojvodova A, Danko J, et al. HER-2 [Ile655Val] polymorphism in association with breast cancer risk: a population-based case-control study in Slovakia. Neoplasma 2006; 3: 49-55.
22. Ameyaw M, Tayeb M, Thornton N, et al. Ethnic variation in the HER-2 codon 655 genetic polymorphism previously associated with breast cancer. J Hum Genet 2002; 47: 172-5.
23. Papadopoulou E, Simopoulos K, Tripsianis G, et al. Allelic imbalance of HER-2 codon 655 polymorphism among different religious/ethnic populations of northern Greece and its association with the development and the malignant phenotype of breast cancer. Neoplasma 2007; 54: 367-81.
24. Papadopoulou E, Tripsianis G, Anagnostopoulos K, et al. The influence of serum HER-2 levels and HER-2 codon 655 polymorphism on breast cancer outcome. Neoplasma 2008; 55: 113-21.
25. Bloom HJG, Richardson WW. Histological grading and prognosis in breast cancer. Br J Cancer 1957; 11: 359-77.
26. Union International contre le Cancer. UICC TNM classification of malignant tumors, 4th ed. Springer-Verlag, Berlin 1992.
27. Sivridis E, Koukourakis MI, Zois CE, et al. LC3A-positive light microscopy detected patterns of autophagy and prognosis in operable breast carcinomas. Am J Pathol 2010; 176: 2477-89.
28. Berberoglu U, Yildirim E, Celen O. Serum levels of tumor necrosis factor alpha correlate with response to neoadjuvant chemotherapy in locally advanced breast cancer. Int J Biol Markers 2004; 19: 130-4.
29. Tesarová P, Kalousová M, Jáchymová M, Mestek O, Petruzelka L, Zima T. Soluble TNF and IL-2 receptors in patients with breast cancer. Med Sci Monit 2000; 6: 661-7.
30. Daraï E, Detchev R, Hugol D, Quang NT. Serum and cyst fluid levels of interleukin (IL)-6, IL-8 and tumour necrosis factor-alpha in women with endometriomas and benign and malignant cystic ovarian tumours. Hum Reprod 2003; 18: 1681-5.
31. Yoshida N, Ikemoto S, Narita K, et al. Interleukin-6, tumour necrosis factor alpha and interleukin-1beta in patients with renal cell carcinoma. Br J Cancer 2002; 86: 1396-400.
32. Michalaki V, Syrigos K, Charles P, Waxman J. Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Cancer 2004; 90: 2312-6.
33. Karayiannakis AJ, Syrigos KN, Polychronidis A, Pitiakoudis M, Bounovas A, Simopoulos K. Serum levels of tumor necrosis factor-alpha and nutritional status in pancreatic cancer patients. Anticancer Res 2001; 21: 1355-8.
34. Jablonska E, Piotrowski L, Grabowska Z. Serum levels of IL-1b, IL-6, TNF-α, sTNF-RI and CRP in patients with oral cavity cancer. Pathol Oncol Res 1997; 3: 126-9.
35. Mantovani G, Macciò A, Mura L, et al. Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites. J Mol Med 2000; 78: 554-61.
36. Sati HI, Greaves M, Apperley JF, Russell RG, Croucher PI. Expression of interleukin-1beta and tumour necrosis factor-alpha in plasma cells from patients with multiple myeloma. Br J Haematol 1999; 104: 350-7.
37. Warzocha K, Ribeiro P, Renard N, et al. Expression of genes coding for the tumor necrosis factor and lymphotoxin ligand-receptor system in non-Hodgkin's lymphomas. Cancer Immunol Immunother 2000; 49: 469-75.
38. Naylor MS, Stamp GW, Foulkes WD, Eccles D, Balkwill FR. Tumor necrosis factor and its receptors in human ovarian cancer. Potential role in disease progression. J Clin Invest 1993; 91: 2194-206. (Pubitemid 23141496)
39. Malik ST, Naylor MS, East N, Oliff A, Balkwill FR. Cells secreting tumour necrosis factor show enhanced metastasis in nude mice. Eur J Cancer 1990; 26: 1031-4.
40. Cubillos S, Scallon B, Feldmann M, Taylor P. Effect of blocking TNF on IL-6 levels and metastasis in a B16-BL6 melanoma/mouse model. Anticancer Res 1997; 17: 2207-11.
41. Qin Z, Krüger-Krasagakes S, Kunzendorf U, Hock H, Diamantstein T, Blankenstein T. Expression of tumor necrosis factor by different tumor cell lines results either in tumor suppression or augmented metastasis. J Exp Med 1993; 178: 355-60.
42. Leek RD, Landers R, Fox SB, Ng F, Harris AL, Lewis CE. Association of tumour necrosis factor alpha and its receptors with thymidine phosphorylase expression in invasive breast carcinoma. Br J Cancer 1998; 77: 2246-51.
43. Kawai N, Tsuji S, Tsujii M, et al. Tumor necrosis factor alpha stimulates invasion of Src-activated intestinal cells. Gastroenterology 2002 ; 122: 331-9.
44. Miller A, Kraiem Z, Sobel E, Lider O, Lahat N. Modulation of human leukocyte antigen and intracellular adhesion molecule-1 surface expression in malignant and nonmalignant human thyroid cells by cytokines in the context of extracellular matrix. Thyroid 2000; 10: 945-50.
45. Kawashima A, Kawahara E, Tokuda R, Nakanishi I. Tumour necrosis factor-alpha provokes upregulation of alpha2beta1 and alpha5beta1 integrins, and cell migration in OST osteosarcoma cells. Cell Biol Int 2001; 25: 319-29.
46. Nozawa F, Hirota M, Okabe A, et al. Tumor necrosis factor alpha acts on cultured human vascular endothelial cells to increase the adhesion of pancreatic cancer cells. Pancreas 2000; 21: 392-8.
47. Carpenter PM, Gatanaga T, Nguyen HP, Hiserodt JC. Lymphocyte and monocyte-induced motility of MCF-7 cells by tumor necrosis factor-alpha. Int J Cancer 1997; 71: 64-70.
48. Varela LM, Stangle-Castor NC, Shoemaker SF, Shea-Eaton WK, Ip MM. TNFalpha induces NFkappaB/p50 in association with the growth and morphogenesis of normal and transformed rat mammary epithelial cells. J Cell Physiol 2001; 188: 120-31.
49. Muss HB, Thor AD, Berry DA, et al. c-erbB-2 expression and response to adjuvant therapy in women with nodepositive early breast cancer. N Engl J Med 1994; 330: 1260-6.
50. Hudziak RM, Lewis GD, Shalaby MR, et al. Amplified expression of the HER2/ERBB2 oncogene induces resistance to tumor necrosis factor alpha in NIH 3T3 cells. Proc Natl Acad Sci U S A 1988; 85: 5102-6.
51. Saglam S, Suzme R, Gurdol F. Serum tumor necrosis factor-alpha and interleukin-2 concentrations in newly diagnosed ERBB2 (HER2/neu) positive breast cancer patients. Int J Biol Markers 2009; 24: 142-6.
52. Lichtenstein A, Berenson J, Gera JF, et al. Resistance of human ovarian cancer cells to tumor necrosis factor and lymphokine-activated killer cells: correlation with expression of HER2/neu oncogenes. Cancer Res 1990; 50: 7364-70.
53. Balkwill F. TNF-alpha in promotion and progression of cancer. Cancer Metastasis Rev 2006; 25: 409-16.
54. Chen G, Goeddel DV. TNF-R1 signaling: a beautiful pathway. Science 2002; 296: 1634-5.